Biodesix partners with Association of Pulmonary APPs for lung cancer education

Biodesix (BDSX) is partnering with the Association of Pulmonary Advanced Practice Providers, or APAPP, to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung blood-based tests, or cancer treatment decision support testing, such as the IQLung blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings. APAPP is the first association solely focused on Advanced Practice Providers working in the realms of pulmonary medicine.